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Abstract 
Cognitive dysfunction is a core feature of dementia and a prominent feature in psychiatric 
disease. As non-redundant regulators of intracellular cAMP gradients, phosphodiesterases 
(PDE) mediate fundamental aspects of brain function relevant to learning, memory, and 
higher cognitive functions. Phosphodiesterase-4B (PDE4B) is an important 
phosphodiesterase in the hippocampal formation, is a major Disrupted in Schizophrenia 1 
(DISC1) binding partner and is itself a risk gene for psychiatric illness. To define the effects 
of specific inhibition of the PDE4B subtype, we generated mice with a catalytic domain 
mutant form of PDE4B (Y358C) that has decreased ability to hydrolyze cAMP. Structural 
modelling predictions of decreased function and impaired binding with DISC1 were 
confirmed in cell assays. Phenotypic characterization of the PDE4BY358C mice revealed 
facilitated phosphorylation of CREB, decreased binding to DISC1, and upregulation of 
',6&DQGȕ-Arrestin in hippocampus and amygdala. In behavioural assays, PDE4BY358C 
mice displayed decreased anxiety and increased exploration, as well as cognitive 
enhancement across several tests of learning and memory, consistent with synaptic 
changes including enhanced long-term potentiation and impaired depotentiation ex vivo. 
PDE4BY358C mice also demonstrated enhanced neurogenesis. Contextual fear memory, 
though intact at 24 hours, was decreased at 7 days in PDE4BY358C mice, an effect 
replicated pharmacologically with a non-selective PDE4 inhibitor, implicating cAMP 
signalling by PDE4B in a very late phase of consolidation. No effect of the PDE4BY358C 
mutation was observed in the pre-pulse inhibition and forced swim tests. Our data establish 
specific inhibition of PDE4B as a promising therapeutic approach for disorders of cognition 
and anxiety, and a putative target for pathological fear memory. 
 
[259 words] 
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Introduction 
Cognitive dysfunction is a core feature of dementia and a prominent feature in major 
psychiatric disorders, such as mood and chronic psychotic disorders. Consequently, there 
is a large unmet need for cognition-enhancing drugs. The second messenger cyclic 
adenosine monophosphate (cAMP) mediates fundamental aspects of brain function 
relevant to learning, memory, and higher cognitive functions (Richter et al, 2013). Memory 
formation relies on expression of genes upregulated by the transcription factor CREB 
(cAMP response element binding protein), which is activated when phosphorylated by PKA 
(protein kinase A) downstream of cAMP. As a consequence, cAMP-specific 
phosphodiesterase enzymes, the sole regulators of cAMP gradients and ultimately CREB, 
are promising targets for the development of cognition-enhancing drugs (Ghavami et al, 
2006; Richter et al, 2013). 
 
The PDE4 family is cAMP-specific and comprises four subtypes (A±D). The 
expression patterns of individual PDE4 subtypes are clearly distinct at the regional and 
cellular level, suggesting that PDE4 subtypes serve non-redundant functions. Non-subtype-
selective brain-penetrant PDE4 inhibitors (targeting all of four subtypes), such as rolipram, 
have shown therapeutic benefit in preclinical models of psychiatric and neurological 
diseases (Ghavami et al, 2006; Richter et al, 2013). These models include memory and 
cognition impairments induced by the N-methyl-D-aspartate (NMDA) receptor antagonist 
MK-801(Davis and Gould, 2005; Zhang et al, 2000), cerebral ischemia-induced neuron loss 
and associated memory deficits in rats (Li et al, 2011a), age-related memory deficits (de 
Lima et al, 2008), and working, reference and associative memory deficits in a transgenic 
PRXVHPRGHORI$O]KHLPHU¶VGLVHDVH (Gong et al, 2004). 
 
©    2015 Macmillan Publishers Limited. All rights reserved.
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However, non-selective PDE4 inhibitors are poorly tolerated in humans due to 
nausea and emesis arising from inhibition of PDE4 in the brainstem (Mori et al, 2010) and 
gut (Menniti et al, 2006) at doses required for clinical effectiveness. Several lines of 
evidence suggest that these adverse effects are related to PDE4D, but not PDE4B 
(Robichaud et al, 2002). Indeed, despite comparable efficacy on other indicators, PDE4B-
selective inhibitors may require doses approaching 100-fold that of PDE4D-selective agents 
to result in emesis, despite similar effect on other measures (Naganuma et al, 2009). Given 
the poor tolerability of non-selective agents, the elucidation of individual PDE4 subtype 
function has emerged as a strategy to guide the development of subtype-selective agents 
with maximal therapeutic utility and tolerability. This has, in part, been facilitated by the 
availability of knock-out (KO) mice deficient in individual PDE4 subtypes. 
 
PDE4 subtypes are constitutively active enzymes containing a highly conserved 
catalytic domain, and then divided into categories defined by the presence of two unique, 
conserved domains: Upstream Conserved Region 1 (UCR1) and 2 (UCR2) (Zhang, 2009). 
The cAMP hydrolytic activity of PDE4B is facilitated and inhibited by PKA (Baillie, 2009) and 
ERK (extracellular signal-related kinase) (Baillie et al, 2000), respectively. The catalytic 
domain and UCR1 contain phosphorylation sites for PKA and ERK, respectively. Five 
PDE4B isoforms have been identified in mammals: the long forms PDE4B1 (736 a.a.), 4B3 
(721 a.a.) and 4B4 (659 a.a.), the short form 4B2 (564 a.a.), and the super-short form 4B5 
(484 a.a.) (Cheung et al, 2007; Fatemi et al, 2008; Shepherd et al, 2003). The catalytic 
domain is common to all isoforms, while the long forms contain UCR1 and UCR2, the short 
form lacks UCR1, and the super-short form has only a portion of UCR2 (Zhang, 2009). 
 
©    2015 Macmillan Publishers Limited. All rights reserved.
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PDE4B is widely distributed throughout the brain in humans, monkeys, and rodents, 
with prominent expression in the cerebral cortex, limbic areas and diencephalon (Cherry 
and Davis, 1999; Lakics et al, 2010; Perez-Torres et al, 2000), as well as white matter 
tracts (Reyes-Irisarri et al, 2008). In cortex, the PDE4B1 isoform predominates, however in 
hippocampus and amygdala all isoforms are expressed (Reyes-Irisarri et al, 2008). 
Consistent with preclinical evidence of cognitive enhancement, changes in expression and 
subcellular localization of PDE4B in hippocampal neurons are associated with long term 
potentiation (LTP) (Ahmed and Frey, 2005), considered one of the cellular mechanisms 
underlying learning and memory (Albensi et al, 2007). Moreover, Pde4b KO mice show an 
increase in the proliferation of neuronal cells in the hippocampal dentate gyrus (Zhang et al, 
2008). Hippocampal slice preparations from Pde4b KO mice show markedly enhanced 
basal postsynaptic responses and long-term depression (Rutten et al, 2011). 
 
Pde4b KO mice display a complex behavioural phenotype. They exhibit a 
moderately anxiogenic behavioral profile with decreased exploratory activity in hole board, 
light-dark transition and (Zhang et al, 2008), decreased locomotor activity in some open 
field tests (Rutten et al, 2011; Siuciak et al, 2008; Zhang et al, 2008), and unaltered 
performance in the elevated plus maze (Siuciak et al, 2008). Pde4b KO mice perform 
normally in the fear conditioning (Rutten et al, 2011) and passive avoidance tests (Siuciak 
et al, 2008; Zhang et al, 2008), and show unaltered shock sensitivity (Rutten et al, 2011) 
and nociceptive responses (Siuciak et al, 2008; Zhang et al, 2008). In the Morris water 
maze, Pde4b KO mice show normal spatial memory acquisition and retention (Rutten et al, 
2011; Siuciak et al, 2008; Zhang et al, 2008), but impaired reversal learning (Rutten et al, 
2011). Acoustic startle response is increased in Pde4b KO mice, while prepulse inhibition of 
the startle response is decreased (Siuciak et al, 2008). They show decreased immobility in 
©    2015 Macmillan Publishers Limited. All rights reserved.
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the forced swim test (Siuciak et al, 2008; Zhang et al, 2008), but not in the tail suspension 
test (Zhang et al, 2008). As expected, however, Pde4b KO mice show resistance to the 
inhibitory effects of rolipram on conditioned avoidance response (Siuciak et al, 2007). 
Though complex, this phenotype provides support for a role for PDE4B in both memory and 
anxiety. 
 
Several lines of evidence have implicated PDE4B in major psychiatric illness, most 
notably schizophrenia. Disruption of PDE4B was identified by a chromosomal translocation 
in two first cousins with schizophrenia (Millar et al, 2005). Subsequently, large population 
genetic analyses of schizophrenia have inconsistently implicated single nucleotide 
polymorphisms within PDE4B (Fatemi et al, 2008; Guan et al, 2012; Kahler et al, 2010; 
Numata et al, 2008; Pickard et al, 2007; Rastogi et al, 2009; Tomppo et al, 2009). While an 
established rare genetic cause of schizophrenia, emerging primate data provide preliminary 
support for a role for PDE4B in the regulation of synaptic and spine plasticity in the 
dorsolateral prefrontal cortex (PFC) and working memory (Paspalas et al, 2013). Thus, 
decreased PDE4B expression in post-mortem brains of patients with schizophrenia (Fatemi 
et al, 2008) may reflect compensatory downregulation of PDE4B to increase synaptic 
plasticity and counter the cognitive deficits associated with this condition, a possibility that 
has not received significant attention. 
 
DISC1 is a large scaffolding protein and that has important interactions with PDE4B 
(Millar et al, 2005; Murdoch et al, 2007). It plays key roles in neuronal development, and is 
a well-established risk factor for major mental illness associated with cognitive dysfunction 
(Blackwood et al, 2001; Porteous et al, 2014). There are five PDE4 binding sites on 100-
kDa full-length DISC1; three of these sites are specific for PDE4B, while two potentially bind 
©    2015 Macmillan Publishers Limited. All rights reserved.
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isoforms from each PDE4 subtype (Murdoch et al, 2007). In response to elevated cAMP 
levels, the shorter 71-kDa DISC1 isoform dissociates from PDE4B, whereas 100-kDa 
DISC1 does not dissociate, likely due to more contact points with PDE4B (Murdoch et al, 
2007). 
 
Though poorly tolerated, non-subtype-selective PDE4 inhibitors have the potential to 
improve cognitive function, and several lines of evidence suggest that PDE4B may be a 
well-tolerated target for anxiety and cognitive enhancement. This study sought to determine 
the effects of specific inhibition of PDE4B by characterizing a catalytic domain mutant form 
of PDE4B (Y358C) that has decreased ability to hydrolyze cAMP. The catalytic domain of 
PDEs is an important pharmacological target, given limited homology between subtypes 
(Sung et al, 2003) and the well characterized relationship between existing PDE inhibitors 
and catalytic domains, notably clinically useful PDE5 inhibitors (Sung et al, 2003) and novel 
PDE4B inhibitors (Goto et al, 2013). We examined the neural and behavioral effects of the 
PDE4B-Y358C mutation in mice with a C57BL/6J genetic background. Our findings 
establish specific inhibition of PDE4B as a promising therapeutic approach for pathology 
affecting memory, anxiety, and fear memory. 
©    2015 Macmillan Publishers Limited. All rights reserved.
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Materials and methods 
 
Generation and structure of PDE4B mutant. The catalytic domain of the PDE4B1 isoform 
(ENSMUSP00000102524) stretches from amino acid residues (a.a.) 305-690 and is 
encoded by Pde4b exons 9-16 (Murdoch et al, 2007). We screened exon 10 (99 bp; a.a. 
341-373) of Pde4b in 7776 male F1 progeny of ENU-mutagenized BALB/cAnN males and 
untreated C3H/HeH females in the MRC Harwell ENU DNA archive. In a single mouse 
(EMRCB/60.3d), we detected an adenine to guanine (A1073G) transition, corresponding to 
a Tyr358 7$&ĺ&\V7*&<&H[FKDQJH6XSSOHPHQWDU\)LJXUHD7KHH[RQ
sequences of the BALB/cAnN and C3H/HeH parental strains are identical, suggesting that 
the PDE4BY358C mutation arose as a result of ENU administration. The tyrosine at position 
358 is present in PDE4B isoforms 1-5 (Supplementary Figure 1b) and is conserved across 
vertebrate species and in mouse PDE4A (Supplementary Figure 1c). 
 
Heterozygous N2 backcross progeny of the founder PDE4BY358C/+ (C3H/HeH x 
BALB/cAnN) F1 male and wild-type (WT) C57BL/6NTac females were backcrossed through 
the male and female lines to C57BL/6J for 10 generations before heterozygotes were 
intercrossed to generate homozygous mutant (PDE4BY358C/Y358C) and WT (PDE4B+/+) 
littermates for phenotypic characterization. PDE4BY358C/+ frozen embryos are available from 
the MRC Mammalian Genetics Unit, UK (har.mrc.ac.uk). 
 
Full methods are available in the Supplementary Methods. 
 
Sex-differences were explored with two-way analysis of variance (ANOVA), however no 
significant Genotype*Sex interactions were observed. For parsimonious interpretation, 
statistical differences are reported using Student's t-test, linear regression, repeated 
©    2015 Macmillan Publishers Limited. All rights reserved.
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measures ANOVA, and Cox regression. Post-hoc tests were performed using least 
significant difference (LSD) when significant genotype*test interactions emerged in ANOVA 
or repeated measures ANOVA. 
 
©    2015 Macmillan Publishers Limited. All rights reserved.
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Results 
At the cAMP binding site, there is an interaction between the central phosphate 
group of cAMP and H406 in WT PDE4B1 (Figure 1a). Though the Y358 residue is located 
within the catalytic domain, it is neither at the site of cAMP binding nor rolipram binding 
(Richter et al, 2001). In the Y358C variant, a conformational change is predicted to the 
binding site by introducing a beta conformational bend bordering the cAMP binding cavity 
around K282. This severely disrupts the docking position of cAMP (Figure 1b) as the side 
chain of K282 bisects the binding site. 
 
PDE4B Y358C alters cAMP signaling and CREB phosphorylation. Using VSV-epitope-
tagged human PDE4B1-Y358C and WT constructs expressed in HEK-293 cells, we found 
that PDE4B1-Y358C has a 27% decreased ability to hydrolyze cAMP (Figure 1c). In mouse 
hippocampus, RT-PCR of PDE4B1-5 did not detect expression differences between 
PDE4BY358C/Y358C and PDE4B+/+ mice (Supplementary Figure 2a). Similarly, western blotting 
did not detect genotypic differences in expression of PDE4B1 in the hippocampus, 
amygdala, prefrontal cortex, and nucleus accumbens associated with Y358C (Figure 1d; 
Supplementary Figure 2b-c). We probed the expression of PDE4A5, due to Y358 
conservation in mouse, and PDE4D3, due to signs of upregulation in Pde4b KO mice 
(Zhang et al, 2008), but found no genotypic differences (Supplementary Figure 2d). 
Hippocampal slices from PDE4BY358C/Y358C brains have similar levels of cAMP as PDE4B+/+, 
but showed a greater cAMP accumulation when challenged with forskolin alone or in 
combination with rolipram (Supplementary Figure 2e). As PDE4B regulates cAMP gradients 
and ultimately CREB, we examined total expression of CREB and its phosphorylation 
(pCREB), finding increased pCREB/CREB in the hippocampi (2.5-fold) and amygdala (1.4-
©    2015 Macmillan Publishers Limited. All rights reserved.
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fold) of PDE4BY358C/Y358C mice (Figure 1e). The Y358C variant of PDE4B is thus normally 
expressed, but has reduced enzymatic activity, which in turn primes CREB signalling. 
 
<&DIIHFWVWKH3'(%SDUWQHUV',6&DQGȕ-Arrestin. Since Y358 occurs within one 
of the three DISC1 binding sites on PDE4B1 (a.a. 352-380) (Murdoch et al, 2007), we 
probed 100-kDa DISC1 binding. Expression of the VSV-epitope-tagged PDE4B1-Y358C 
and WT constructs in HEK-293 cells revealed decreased DISC1 immunoprecipitation 
(Figure 1f), which was paralleled in co-immunoprecipitation from PDE4BY358C/Y358C brains 
(Figure 1g). Western blotting revealed that the expression of DISC1 was unaltered in the 
prefrontal cortex and nucleus accumbens (Supplementary Figure 1c-d), but was increased 
3-fold in the hippocampus and 1.6-fold in the amygdala of PDE4BY358C/Y358C mice (Figure 
1d). The DISC1 upregulation was confirmed using VSV-epitope-tagged human PDE4B1-
Y358C and WT constructs expressed in HEK-293 cells (Figure 1h). ȕ-Arrestins are known 
to recruit PD(WRWKHȕ-adrenoreceptor, thus controlling PKA activity at the membrane 
(Baillie et al, 2003; Li et al, 2011b). Though PDE4B1-ȕ-Arrestin1/2 binding was not impaired 
in PDE4BY358C/Y358C mice (Supplementary Figure 2f), ȕ-Arrestin1/2 was increased 1.6-fold in 
the hippocampus and 1.3-fold in the amygdala (Figure 1d), but not in prefrontal cortex and 
nucleus accumbens (Supplementary Figure 2b-c). 
 
PDE4B Y358C mice display decreased anxiety and greater exploratory behavior. In 
the elevated plus maze, mice face a conflict between aversion to open arms and motivation 
to explore these arms. PDE4BY358C/Y358C mice spent more time in the open arms and made 
more exploratory head dips and passages than PDE4B+/+ mice (Figure 2a). In a novel open 
field, PDE4BY358C/Y358C mice displayed greater ambulation and rearing activity, and spent 
more time in the aversive center of the arena (Figure 2b). Further, PDE4BY358C/Y358C mice 
12 
 
spent more time in the bright compartment of the light-dark box (Figure 2c). We exploited 
murine aversion to cat odors (Vyas et al, 2007) by baiting a T-maze with food pellets in one 
arm and bobcat urine in the opposite arm. PDE4B+/+ mice avoided the bobcat urine arm, 
whereas PDE4BY358C/Y358C mice explored both arms equally (Figure 2d). This difference 
was not attributable to impaired olfaction (Supplementary Figure 3a). 
 
In a holeboard test of exploratory behavior, PDE4BY358C/Y358C mice performed more 
nose-pokes than PDE4B+/+ mice (Figure 2e). When attempting to find buried food, 
PDE4BY358C/Y358C mice engaged in greater exploratory burrowing than PDE4B+/+ mice 
(Figure 2f). This was not merely hyperlocomotion (Supplementary Figure 3b). 
PDE4BY358C/Y358C mice thus exhibited a consistent pattern of lower anxiety, and greater 
exploratory behavior and risk-taking. 
 
We did not observe differences in depressive-like behaviour using the forced swim 
test (Supplementary Figure 3b). 
 
PDE4B Y358C mice display enhanced learning and memory. In the Y-maze 
spontaneous alternation test, PDE4BY358C/Y358C mice exhibited improvements in working 
spatial memory (Figure 3a). In the Morris water maze, PDE4BY358C/Y358C mice located the 
escape platform faster than PDE4B+/+ mice in both acquisition and reversal training trials 
(Figure 3b), an effect not attributable to swimming time or speed (Supplementary Figure 3b-
c). Moreover, PDE4BY358C/Y358C mice had improved performance compared to PDE4B+/+ 
mice in probe trials 24 hr after the last acquisition and reversal trials (Figure 3b). In a social 
recognition test, PDE4BY358C/Y358C mice demonstrated enhanced long-term (24 hr) memory 
of a familiar juvenile compared with PDE4B+/+ mice (Figure 3c). 
©    2015 Macmillan Publishers Limited. All rights reserved.
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Object location recognition is a hippocampus-dependent task exploiting the natural 
exploratory activity of rodents toward spatial novelty to assess the detection of spatial 
relocation of a known object (Stupien et al, 2003). PDE4BY358C/Y358C and PDE4B+/+ mice 
displayed similar preferences for displaced objects following a 10-minute acquisition period, 
but only PDE4BY358C/Y358C mice demonstrated a preference for displaced objects when the 
acquisition period was reduced to 5 minutes (Figure 3d). We have previously shown that 
decreasing environmental threat by dimming the lights results in increased exploration with 
consequent improvement in memory (Saab et al, 2009). Since PDE4BY358C/Y358C mice 
already display increased exploratory behavior under typical room lighting (µbright lights¶) 
(Figure 2), we sought to increase the environmental threat by exposing mice to brighter 
lights and a transparent arena floor at 1m elevation. In this more aversive environment, 
PDE4B+/+ mice failed to show preference for displaced objects following 10 minutes of 
acquisition, but the displaced object preference of PDE4BY358C/Y358C mice was maintained, 
even when acquisition was limited to 5 minutes (Figure 3d). 
 
PDE4B Y358C mice display altered fear memory. In the fear conditioning paradigm, 
PDE4BY358C/Y358C mice demonstrated levels of freezing comparable with PDE4B+/+ mice in 
the hippocampus-dependent contextual memory test 24 hr after conditioning, but showed 
decreased freezing in the amygdala-dependent cued memory test (Figure 3e). When a 
portion of this cohort was retested 7 days after conditioning, PDE4BY358C/Y358C mice 
displayed less freezing to the context than PDE4B+/+ mice (Supplementary Figure 4a). 
Therefore, 7-day fear memory was tested in an independent cohort, in which 
PDE4BY358C/Y358C mice showed lower levels of both contextual freezing and cued freezing 
after 7 days, in the absence of exposure at 24 hrs (Figure 3f). The PDE4BY358C/Y358C 
©    2015 Macmillan Publishers Limited. All rights reserved.
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decreased freezing is not attributable to altered nociception, or to sensorimotor processing 
as assessed using the Pre-Pulse Inhibition test (Supplementary Figure 4b-d). 
 
To further examine the effect of PDE4B functional impairment on 7-day fear memory, 
twice daily injections of the non-selective PDE4 inhibitor rolipram (1mg/kg) were 
administered to PDE4B+/+ mice from 24 hr to 6 days after conditioning. Compared to 
vehicle-treated controls, the rolipram-treated mice exhibited a contextual memory-specific 
reduction in freezing (Figure 3g), supporting our PDE4BY358C/Y358C findings. 
 
PDE4B Y358C mice display altered synaptic plasticity. Hippocampal CA1 
electrophysiological experiments were used to explore synaptic plasticity in 
PDE4BY358C/Y358C mice. The Y358C mutation did not affect basal synaptic transmission 
(Supplementary Figure 5). We applied forskolin, an adenylyl cyclase activator, and found 
increased potentiation in PDE4BY358C/Y358C hippocampal slices, confirming decreased 
PDE4B-Y358C cAMP hydrolytic function (Figure 4a). To examine the effect of sustained 
electrical stimulation on LTP in PDE4BY358C/Y358C mice, we utilized high frequency (100-Hz) 
trains and varied their number. Following tetanic stimulation with four trains, 
PDE4BY358C/Y358C slices demonstrated enhanced potentiation (Figure 4b). Given the rapid 
acquisition observed in object recognition (Figure 3d), we employed a single 100-Hz train, 
which is below the typical threshold for LTP (Albensi et al, 2007). PDE4BY358C/Y358C slices 
showed evidence of facilitation while PDE4B+/+ slices, as expected, demonstrated non-
significant potentiation (Figure 4c). We examined synaptic depression in PDE4BY358C/Y358C 
mice, but observed no change in slices from 16-17-day-old mice after 900 pulses of 1-Hz 
stimulation (Figure 4d). As our behavioral studies were conducted on 8-12 week old mice, 
we also studied an adult form of synaptic depression ± depotentiation ± whereby tetanic 
©    2015 Macmillan Publishers Limited. All rights reserved.
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stimulation is followed by low frequency stimulation (Grunwald et al, 2001). Depotentiation 
restored fEPSP slopes to baseline in PDE4B+/+ slices but resulted in less synaptic 
depression in PDE4BY358C/Y358C slices (Figure 4e). Paired-pulse facilitation showed no 
evidence that Y358C impaired presynaptic short-term plasticity (Figure 4f). 
 
PDE4B Y358C mice display increased dendritic spine density and hippocampal 
neurogenesis. The combined administration of rolipram and antidepressants to rodents 
results in increased BDNF expression (Fujimaki et al, 2000) and CA1 spine density 
(Marchetti et al, 2010). In mouse models RI$O]KHLPHU¶VGLVHDVHUROLSUDPUHVWRUHVGHQGULWLF
spine density (Smith et al, 2009), while Disc1 mutant mice with impaired DISC1-PDE4B 
binding show alterations in hippocampal spine density (Lee et al, 2011). We therefore 
sought to examine dendritic spine density in PDE4BY358C/Y358C mice, focusing on the 
hippocampus and lateral amygdala. Using the Thy1-GFP transgene (Feng et al, 2000) as a 
reporter for dendritic spines, we identified greater spine densities in both the hippocampus 
and lateral amygdala of PDE4BY358C/Y358C mice (Figure 5a). 
 
Enhanced adult hippocampal neurogenesis has been observed in both Pde4b and 
Pde4d KO mice (Li et al, 2011b; Zhang et al, 2008). In light of data indicating that adult 
hippocampal dentate neurogenesis destabilizes contextual fear memory (Akers et al, 2014), 
we probed neurogenesis in conjunction with fear conditioning. Using daily injections of 5-
bromo-2'-deoxyuridine (BrdU; 50 mg/kg, i.p.) for four days following fear conditioning, we 
examined neurogenesis in the hippocampal dentate gyrus of PDE4BY358C/Y358C mice in 
comparison with PDE4B+/+ mice that received rolipram (1mg/kg) or vehicle twice daily for 6 
days. Increased numbers of dentate BrdU+ and doublecortin+ cells were observed in 
PDE4BY358C/Y358C mice compared with both rolipram-treated and vehicle-treated PDE4B+/+ 
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mice (Figure 5b). However, no significant relationship was observed between adult 
hippocampal neurogenesis and contextual freezing with linear regression (Figure 5c). 
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Discussion 
The present study sought to determine the neural and behavioral effects of a catalytic 
domain mutant form of PDE4B (Y358C) that has decreased ability to hydrolyze cAMP. 
Consistent with previous data suggesting the involvement of the Y358 residue in the 
interaction of PDE4B with DISC1 (Murdoch et al, 2007), our comparative molecular 
modelling suggested that the cysteine substitution resulted in a conformational modification 
rendering the DISC1 interaction site inaccessible. Confirmed in cell culture and brain tissue, 
the decreased binding of PDE4B-Y358C to DISC1 was associated with increased 
H[SUHVVLRQRI',6&DQGȕ-arrestin1/2 in the amygdala and hippocampus, perhaps 
indicating compensatory mechanisms to normalize PDE4B activity. Moreover, our 
modelling suggested impaired cAMP binding due to tertiary changes as a result of the 
Y358C substitution. Indeed, 27% impairment in cAMP hydrolytic ability of PDE4B1-Y358C 
observed in vitro is proportional to that of physiological regulation by phosphorylated ERK 
(Baillie et al, 2000). The importance of the Y358C alteration was confirmed ex vivo in 
forskolin-challenged hippocampal slices, which demonstrated rapid cAMP accumulation 
and sustained potentiation at Schaffer CA1 collaterals. 
 
PDE4BY358C/Y358C mice consistently demonstrated low levels of anxiety in several 
tests, and even failed to demonstrate the natural robust innate fear response to cat odor. A 
decreased fear response to cat odor is also shown by mice infected with Toxoplasma gondii 
(Vyas et al, 2007), a schizophrenia risk factor that localizes to the lateral amygdala involved 
in both innate and learned fear (LeDoux, 2000). Pde4b KO mice show anxiogenic-like 
behaviour in the holeboard and light-dark transition tests (Zhang et al, 2008), and therefore 
null mutation (KO) and missense mutation (Y358C) of Pde4b appear to have opposite 
effects on some tests of anxiety (Rutten et al, 2011; Siuciak et al, 2008; Zhang et al, 2008).  
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Such phenotypic differences between mice which harbor a missense mutation or null 
mutation (KO) of the same gene are not uncommon; for example, missense mutation I810N 
(Kirshenbaum et al, 2013) and KO (Ikeda et al, 2013) alleles of the Na+,K+-ATPase D3 gene 
are reported to have opposite effects on the beam walking assay. Our finding that reduced-
function of PDE4B by a catalytic domain mutation results in anxiolytic effects is consistent 
with anxiolysis observed with non-selective PDE4 inhibitors in rodents (Li et al, 2009b; 
Rutter et al, 2014; Silvestre et al, 1999) and primates (Rutter et al, 2014). Together this 
data suggests that the anxiolytic effects of non-selective PDE4 inhibitors may be PDE4B-
dependent.  
 
In humans and mice, exploratory tendencies are predictive of general cognitive 
abilities (Matzel et al, 2006). However, an increased exploratory tendency does not equate 
to improvement in general cognitive performance (Light et al, 2011; Light et al, 2008), 
perhaps suggesting a common substrate yet lack of causality between these factors. 
RHGXFLQJDQHQYLURQPHQW¶VDYHUVLYHFKDUDFWHULVWLFVcan shift the motivation underlying 
exploration, resulting in learning facilitation (Saab et al, 2009). The PDE4B-Y358C mutation 
decreased fear responses and increased exploration in mice, and we observed a consistent 
pattern of cognitive enhancement in PDE4BY358C/Y358C mice in non-aversive tests. The 
resistance shown by PDE4BY358C/Y358C mice to the negative influence of environmental 
threat on object recognition memory formation suggests dissociation between fear and 
memory formation. Our learning and memory as well as synaptic findings are consistent 
with the PDE4B-Y358C PXWDQW¶Vreduced cAMP hydrolytic activity and facilitation of CREB 
phosphorylation (Tully et al, 2003). 
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In fear conditioning, inputs are received within the lateral amygdala to form an 
association between the auditory tone (conditioned stimulus) and the foot-shock 
(unconditioned stimulus) (LeDoux, 2000). The deficits in PDE4BY358C/Y358C cued memory 
PD\UHIOHFWDOWHUHGODWHUDODP\JGDODIXQFWLRQFRQVLVWHQWZLWKȕ-Arrestin upregulation and 
the ȕ-Arrestin±PDE4 complex required for fear conditioning (Li et al, 2009a). Yet 
PDE4BY358C/Y358C mice had intact contextual (hippocampal) fear memory at 24 hours, which 
is considered sufficient time for the formation of long-term memories (Tully et al, 2003). 
Pde4b KO mice, by contrast, have shown no differences in context-dependent and cue-
dependent fear memory tests at 24 hours (Rutten et al, 2011). The decrease in contextual 
freezing exhibited by PDE4BY358C/Y358C mice when tested at 7 days is unlikely to represent 
extinction of fear memory, as lower contextual freezing after 7 days was observed 
independent of pre-exposure to the context at 24 hours. Our data suggest that this is due to 
PDE4B dysfunction rather than disrupted interaction with DISC1 because the 
PDE4BY358C/Y358C fear conditioning phenotype was replicated in control mice given 
subchronic rolipram, which inhibits PDE4B activity but does not affect binding to DISC1. 
Moreover, the replication of the phenotype when rolipram was initiated 24 hours after fear 
conditioning suggests that PDE4B is involved in a very late process required for long-term 
memory persistence. 
 
Impaired regulation of cAMP signalling in the hippocampus by PDE4B may impair a 
very late-phase of consolidation, perhaps by poor coordination of the late-phase protein 
transcription required for long-term memory persistence. Disruption of late-phase processes 
by injecting anisomycin or BDNF-antibodies into CA1 of the hippocampus 12 hours after 
fear conditioning leads to a similar phenotype, with intact freezing at 48 hours but 
decreased freezing after 7 days (Bekinschtein et al, 2007). Moreover, this phenotype has 
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also been reported with antidepressants given 12 hours after fear conditioning (Slipczuk et 
al, 2013). However, unlike the PDE4BY358C/Y358C phenotype, these previous studies 
detected no change in fear memory at 7 days if the interventions occurred at or after 24 
hours (Bekinschtein et al, 2007; Slipczuk et al, 2013). 
 
Alternatively, the degree to which the PDE4B-Y358C function facilitates the 
acquisition of new associations and formation of new synapses may lead to loss of 
behavioural specificity over time. Moreover, neurogenesis in PDE4BY358C/Y358C mice may 
destabilize the fear trace (Akers et al, 2014), yet in our mice this was not linearly related to 
contextual fear memory. Our findings suggest that PDE4B inhibition is a putative 
therapeutic approach in overly persistent fear memories, typified by post-Traumatic Stress 
Disorder (PTSD), which would benefit from a larger prophylactic window. 
 
In summary, the Y358C reduced-function PDE4B mutant resulted in increased 
phosphorylation of CREB, decreased binding of PDE4B to DISC1, and upregulation of 
',6&DQGȕ-Arrestin in the hippocampus and amygdala. PDE4BY358C/Y358C mice displayed 
a phenotype of decreased anxiety, increased exploration, and cognitive enhancement 
across several tests of learning and memory, in parallel with hippocampal synaptic changes 
including enhanced long-term potentiation, impaired depotentiation, and enhanced 
neurogenesis. Contextual fear memory, though intact at 24 hours, was decreased at 7 days 
and replicated pharmacologically with a non-selective PDE4 inhibitor. Our data establish 
specific inhibition of PDE4B as a promising therapeutic approach for disorders of memory 
and anxiety. Future studies should examine the neural and behavioral effects of brain-
penetrant PDE4B-selective inhibitors in psychiatric and neurologic models. 
[4,332 words] 
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Figure Legends 
 
Figure 1. Biochemical consequences of PDE4B-Y358C mutation. (a) Wild-type 
PDE4B1 with accessible Y358 and H406 interacting with cAMP. (b) Mutant PDE4B1 with 
inaccessible 358C and disrupted cAMP docking position. (c) cAMP hydrolytic function of 
VSV-epitope-tagged PDE4B1-Y358C and WT constructs expressed in HEK-293 cells 
(paired-t(5)=2.90, p<0.05). (d) No PDE4B1 expression differences in hippocampus or 
amygdala. PDE4BY358C/Y358C PLFHKDYHLQFUHDVHGH[SUHVVLRQRI',6&DQGȕ-arrestin1,2 
VSHFLILFWRWKHKLSSRFDPSXVȕ-Arrestin1,2 t(6)=2.66, p<.05; DISC1 t(6)=5.06, p<0.01) and 
DP\JGDODȕ-Arrestin1,2 t(14)=2.94, p<0.05; DISC1 t(6)=6.56, p<0.001). (e) Increased 
phosphorylation of CREB in the PDE4BY358C/Y358C hippocampus (t(6)=5.17, p<0.01) and 
amygdala (t(6)=2.89, p<0.05). (f) Lower DISC1 immunoprecipitation in HEK-293 cells 
expressing VSV-epitope-tagged Y358C PDE4B1 (t(4)=2.90, p<0.05). (g) Whole brain co-
immunoprecipitation demonstrating impaired PDE4B1-DISC1 binding in PDE4BY358C/Y358C 
mice (t(9)=3.74, p<0.01). (h) Increased ',6&W SEXWQRWȕ-Arrestin1,2 
(t(4)=1.39, ns) expression in HEK-293 cells expressing VSV-epitope-tagged PDE4B1-
Y358C constructs. Means ± SEM in all graphs, * p<0.05, **p<0.01, ***p<0.001. 
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Figure 2. Anxiety and exploration. (a) Elevated plus maze. PDE4BY358C/Y358C mice 
(n=9M/6F) spent less time than PDE4B+/+ (n=10M/5F) in the closed arms (t(28)=3.28, 
p<0.01), more time in the open arms (t(28)=2.09, p<0.05), performed more head dips 
(t(28)=3.66, p<0.01) and more passages between arms (t(28)=2.59, p<0.05). (b) Open 
field. PDE4B358C/358C mice (n=13M/8F) spent more time than PDE4B+/+ (n=12M/9F) in the 
centre of the arena (Time F(5, 200)=4.43, p<0.001; Genotype F(1, 200)=5.01, p<0.05; 
Time*Genotype F(1, 200)=0.84, ns), more rearing movements (Time F(5, 200)=21.83, 
p<0.0001; Genotype F(1, 200)=7.30, p<0.01; Time*Genotype F(1, 200)=3.28, p<0.01), and 
more total beam breaks (Genotype: F(1, 200)=8.06, p<.01); Time: F(5, 200)=127.1, 
S*HQRW\SH7LPH) Sc) Light-dark box. PDE4BY358C/Y358C 
(n=6M/5F) mice spent more time than PDE4B+/+ (n=7M/5F) in the light compartment 
(t(21)=2.16, p<0.05). (d) Aversion to cat odor. PDE4B+/+ (n=5M/3F) mice avoided the 
bobcat urine baited arm whereas PDE4B358C/358C (n=5M/5F) visited the both arms equally 
(t(16)=8.71, p<0.0001). (e) Holeboard. PDE4BY358C/Y358C mice (n=6M/1F) performed more 
hole pokes than controls (n=6M/2F); t(13)=3.54, p<0.01). (f) Food burrowing. 
PDE4BY358C/Y358C mice (n=5M/5F) spent significantly more time foraging than PDE4B+/+ 
(n=5M/5F;t(18)=2.42, p<0.05). Means ± SEM in all graphs, * p<0.05, **p<0.01, ***p<0.001. 
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Figure 3. Cognitive enhancement and fear memory. (a) Y-maze. PDE4BY358C/Y358C mice 
(n=11M/11F) demonstrated improved working memory with more spontaneous alternation 
(n=10M/17F; t(47)=3.02, p<0.01) and increased arm entry (t(47)=2.27, p<0.05) than 
PDE4B+/+. (b) Morris water maze. PDE4BY358C/Y358C mice (n=4M/4F) demonstrated more 
rapid spatial memory acquisition than PDE4B+/+ (n=6M/3F) during the training (Genotype 
F(1,45)=2.27, p=0.059); Genotype*Time F(3,45)=4.61, p<0.01) and reversal learning 
(Genotype F(1,30)=8.80, p<0.01; Genotype*Day F(2,30)=3.73, p<0.05) phases. 
PDE4BY358C/Y358C mice spent more time in the target quadrant on the probe trial after 
training (Quadrant F(3, 60)=133.6, p<.0001; Genotype*Quadrant F(3,60)=20.31, p<.0001) 
and after reversal learning (Quadrant F(3, 32)=110.6, p<.0001; Genotype*Quadrant 
F(3,32)=21.22, p<.0001). (c) Social recognition. PDE4BY358C/Y358C mice exhibit improved 
social memory (Y358C n=7M vs WT n=9M; t(14)=3.13, p<0.01). (d) Displaced object 
ORFDWLRQUHFRJQLWLRQPLQDFTXLVLWLRQLQµVDIH¶HQYLURQPHQWWRSOHIWUHYHDOVFRPSDUDEOH
GLVSODFHGREMHFWSUHIHUHQFHEHWZHHQJHQRW\SHVPLQDFTXLVLWLRQLQDµVDIH¶HQYLURQPHQW
(top right; Y358C 10M/2F vs WT 10M/2F; t(22)=4.58, p<0.0001), 5 min acquisition in a 
µaversive¶HQYLURQPHQWERWWRPULJKWW SDQGPLQDFTXLVLWLRQLQD
µaversive¶HQYLURQPHQWERWWRPOHIWW SDOOUHYHDOJUHDWHUGLVSODFHGREMect 
preference in PDE4BY358C/Y358C mice. (e) Fear conditioning ± 24 hours. PDE4BY358C/Y358C 
mice (n=7M/5F) exhibit normal contextual and decreased cued freezing compared to 
PDE4B+/+ (n=6M/6F) 24 hours after fear conditioning (t(22)=1.99, p<0.05). (f) Fear 
conditioning ± 7 days. PDE4BY358C/Y358C (n=7M/6F) mice exhibit decreased contextual 
(t(25)=2.08, p<0.05) and decreased cued (t(25)=4.08, p<0.001) freezing compared to 
PDE4B+/+ (n=10M/4F) 7 days after fear conditioning. (g) Fear conditioning ± rolipram. 
Subchronic rolipram (1 mg/kg twice daily) reproduced decreased contextual freezing 7 days 
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after training in +/+ mice (rolipram n=8M/1F vs vehicle n=7M/1F; t(15)=2.27, p<0.05). 
Means ± SEM in all graphs, * p<0.05, **p<0.01, ***p<0.001. 
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Figure 4. Synaptic plasticity in Schaffer collaterals of hippocampal CA1 neurons. (a) 
Enhanced potentiation after forskolin challenge in PDE4BY358C/Y358C slices (t(7)=2.62, 
p<0.05; PDE4BY358C/Y358C 4 slices from 3 mice; PDE4B+/+ 5 slices from 3 mice). (b) 
Facilitated and stable LTP upon tetanic stimulation in PDE4BY358C/Y358C slices (t(18)=2.36, 
p<0.05; PDE4BY358C/Y358C 11 slices from 10 mice, PDE4B+/+ 10 slices from 6 mice). (c) 
Facilitated and stable LTP from brief tetanic stimulation in PDE4BY358C/Y358C slices 
(t(10)=2.83, p<0.05; PDE4BY358C/Y358C 6 slices from 5 mice, PDE4B+/+ 6 slices from 6 mice). 
(d) Low-frequency stimulation results in comparable LTD (PDE4BY358C/Y358C 6 slices from 3 
mice, PDE4B+/+ 6 slices from 3 mice). (e) Impaired depotentiation in PDE4BY358C/Y358C mice 
(PDE4BY358C/Y358C 7 slices from 7 mice, PDE4B+/+ 9 slices from 9 mice). (f) Y358C mutation 
does not affect pre-synaptic short-term plasticity. Representative fEPSPs are presented for 
each experiment (PDE4B+/+ gray, PDE4BY358C/Y358C black). For panels a-d the scale 
represents 10ms and 0.2mV, and 100ms and 0.2mV in panel f. Means ± SEM in all graphs, 
* p<0.05, **p<0.01, ***p<0.001. 
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Figure 5. Dendritic spine density and neurogenesis. (a) Increased dendritic spine 
density in both the hippocampus (34 segments from 4 Thy1-GFP mice; t(32)=3.57, p<0.01) 
and the amygdala (43 segments from 4 Thy1-GFP mice; t(41)=3.01, p<0.01) of 
PDE4BY358C/Y358C mice. (b) Increased dentate neurogenesis among PDE4BY358C/Y358C mice 
compared to control mice receiving rolipram 1 mg/kg or vehicle twice daily for 6 days 
(F(2,12)=8.80,p<.01). (c) Subgranual layer neurogenesis was not related to contextual 
freezing 7 days after fear conditioning (F(1, 13)=2.01, ns). 
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Supplementary Figure 1. (a) Sequencing chromatogram demonstrated an A1073G 
transition in a conserved region resulting in the Y358C missense mutation. (b) PDE4B 
isoform alignment (blue ± UCR2; red ± catalytic domain; gray ± conserved amino acid 
residues; yellow ± Y358C position). (c) Y358 is conserved across species and in PDE4A. 
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Supplementary Figure 2. (a) Real-Time PCR analysis of hippocampal PDE4B isoforms 
(PDE4BY358C/Y358C n=4, PDE4B+/+ n=4, F(1,4)=0.20, ns). (b-c) Representative western blots 
IRU3'(%',6&DQGȕ-Arrestin1,2 for the prefrontal cortex and nucleus accumbens. (d) 
Expression of PDE4A5 and PDE4D3 in hippocampus. (e) cAMP quantification in 
hippocampal slices. (f) Representative co-IP for PDE4B1-ȕ-Arrestin1,2. 
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Supplementary Figure 3. (a) PDE4BY358C/Y358C mice do not demonstrate impaired olfactory 
function (t(18)=1.23, ns). (b) PDE4BY358C/Y358C (n=6M/5F) mice do not demonstrate changes 
compared to PDE4B+/+ mice (n=8M/10F) in depressive behaviors or hyperlocomotion in the 
forced swim test (t(27)=0.33, ns). (c) Comparable swimming speed in the Morris water 
maze (t(18)=1.23, ns). 
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Supplementary Figure 4. (a) PDE4BY358C/Y358C (n=4M/4F) mice demonstrated normal 
contextual fear at 24 hours compared to PDE4B+/+ mice (n=6M/7F), but when retested after 
7 days they demonstrate decreased contextual fear (Time F(1,19)=10.77, p<0.01; 
Genotype F(1,19)=1.17, ns; Genotype*Time F(1,19)=5.16, p<0.05). (b) PDE4BY358C/Y358C 
mice displayed normal nociception (Cox regression B=-0.53, SE=0.68, Wald=0.62, ns). 
PDE4B+/+ (n=2M/2F) and PDE4BY358C/Y358C (n=4M/3F) mice were placed in the fear 
conditioning chambers and footshock current was manually controlled. Beginning at 0.10 
mA, footshocks were administered for 10 seconds. If the animal did not vocalize or perform 
a vertical jump, the animal rested for 30 seconds prior to receiving a shock of greater 
intensity (0.10 mA increases). (c) PDE4BY358C/Y358C mice do not demonstrate sensorimotor 
changes in acoustic startle response (PDE4BY358C/Y358C n=6M/5F vs PDE4B+/+ n=9M/9F; 
t(27)=1.04, ns). (d) PDE4BY358C/Y358C mice do not demonstrate impaired prepulse inhibition. 
PDE4BY358C/Y358C mice (n=6M/5F) and PDE4B+/+ mice (n=9M/9F) had comparable prepulse 
inhibition for all prepulse intensities (Genotype: F(1, 54)=0.83, ns; Prepulse F(2, 54)=4.53, 
p<.05; Genotype*Prepulse (F2, 54)=0.79, ns). 
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Supplementary Figure 5. PDE4B-Y358C mutation does not affect basal synaptic 
transmission. Input-output function representing presynaptic volley size and corresponding 
fEPSP slope. 
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